Docetaxel, Carboplatin, and Bevacizumab in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery

DISEASE CHARACTERISTICS: * Histologically confirmed non-small cell lung cancer * No squamous cell carcinoma * No histology in close proximity to a major vessel * Resectable stage IB-IIIA disease * No CNS or brain metastases PATIENT CHARACTERISTICS: * ECOG performance status 0-1 * Absolute neutrophil count ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Hemoglobin ≥ 8.0 g/dL * Bilirubin normal * Creatinine ≤ 1.5 mg/dL * Urine protein:creatinine \< 1.0 * Alkaline phosphatase (AP), AST, and ALT must meet 1 of the following criteria: * AP normal AND AST and ALT ≤ 5 times upper limit of normal (ULN) * AP ≤ 2.5 times ULN AND AST and ALT ≤ 1.5 times ULN * AP ≤ 5 times ULN AND AST and ALT normal * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for at least 3 months after completion of study treatment * Adequate pulmonary and cardiovascular function to tolerate surgical resection * No cavitation or history of hemoptysis (i.e., bright red blood ≥ ½ teaspoon) * No existing peripheral neuropathy ≥ grade 1 * No known history of severe hypersensitivity reaction to drugs formulated with polysorbate 80 * No history of serious systemic disease, including any of the following: * Myocardial infarction within the past 6 months * Uncontrolled hypertension (i.e., blood pressure \> 150/110 mm Hg on medication) * Unstable angina * New York Heart Association class II-IV congestive heart failure * Unstable symptomatic arrhythmia requiring medication * Patients with chronic atrial arrhythmia (i.e., atrial fibrillation or paroxysmal supraventricular tachycardia) are eligible * Clinically significant peripheral vascular disease (i.e., grade II or higher) * No history of significant neurological or psychiatric condition * No known active infection within the past 14 days * No serious, nonhealing wound, ulcer, or bone fracture * No evidence of bleeding diathesis or coagulopathy * No stroke within the past 6 months * No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days * No other serious illness or medical condition * No active infection * No other currently active malignancy except nonmelanoma skin cancer * Malignancies for which therapy has been completed and are considered to have ≤ 30% chance of risk of relapse are not considered active PRIOR CONCURRENT THERAPY: * No prior chemotherapy or VEGF inhibitor * No prior (i.e., within the past 4 weeks), concurrent, or anticipated participation in another experimental drug study except a Genentech-sponsored bevacizumab cancer study * No major surgical procedure, open biopsy, or significant traumatic injury within the past 28 days * No anticipation for major surgical procedure during study treatment * No fine-needle aspiration or core biopsy within 7 days prior to study entry * No concurrent full-dose anticoagulation * No other concurrent chemotherapy, immunotherapy, radiotherapy, or investigational therapy for this cancer